Skip to content

QDOT Based PVI for Atrial Fibrillation Treatment - The peQasus Study

Very High-Power Short-duration Ablation Utilizing the QDOT Micro Ablation Catheter for Pulmonary Vein Isolation - A Multicenter Study.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05710822
Acronym
peQasus
Enrollment
300
Registered
2023-02-02
Start date
2023-01-31
Completion date
2023-06-30
Last updated
2023-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Catheter abaltion, very high-power short-duration, QDOT

Brief summary

PeQasus is a worldwide, retrospective, multicenter analysis focusing on QDOT based PVI. Data of at least 300 patients with QDOT based PVI will be collected. All data will be evaluated after anonymization. Primary endoints are efficacy and safety.

Interventions

DEVICEpulmonary vein isolation

pulmonary vein isolation utilizing the QDOT Micro ablation catheter

Sponsors

University of Luebeck
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Suitable for PVI

Exclusion criteria

* Non suitable for PVI

Design outcomes

Primary

MeasureTime frameDescription
Safety (Stroke)PeriproceduralPeriprocedural complications (occurence of stroke)
Safety (Bleeding)PeriproceduralPeriprocedural complications (occurence of puncture site bleeding)
Efficacy of the procedurePeriproceduralAcute PVI
Saftey (Cardiac tamponade)PeriproceduralPeriprocedural complications (occurence of cardiac tamponade)

Secondary

MeasureTime frameDescription
Procedure timePeriprocedural
LA dwelling timePeriprocedural
First pass isolationPeriprocedural
12 months follow-up91 days - 12 months after the procedureOccurence of aftrial fibrillation or atrial tachycardia \>30 Seconds between 91 days and 12 months of follow-up

Contacts

Primary ContactChristian-Hendrik Heeger, MD
christian.heeger@gmx.net004945150075293

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026